Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00290017 · ClinicalTrials.gov registry record · Phase 3
Study of Talabostat and Pemetrexed vs. Pemetrexed in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) After Failure of Platinum-Based Chemotherapy
A Phase 3 study, sponsored by Point Therapeutics.
- Terminated
- Registry status
- Phase 3
- Development phase
- 400
- Enrollment target
NCT00290017 is a Phase 3 study that was terminated before completion, run by Point Therapeutics. The registered enrollment target is 400 participants.
The verdict
NCT00290017, a Phase 3 study, was terminated before completion, sponsored by Point Therapeutics.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 400 participants
- Enrollment target
Study Summary
This Phase 3 study will compare the efficacy of talabostat plus pemetrexed to pemetrexed plus placebo in patients with Stage IIIB/IV NSCLC who have failed a platinum-based chemotherapy regimen.
Interventions
- DRUG pemetrexed
- DRUG talabostat
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2006-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00290017
The ClinicalTrials.gov registry entry for NCT00290017 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 400 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Point Therapeutics, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which pemetrexed is the first listed.
NCT00290017 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00290017 about?
NCT00290017 is a clinical study titled "Study of Talabostat and Pemetrexed vs. Pemetrexed in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) After Failure of Platinum-Based Chemotherapy". This Phase 3 study will compare the efficacy of talabostat plus pemetrexed to pemetrexed plus placebo in patients with Stage IIIB/IV NSCLC who have failed a platinum-based chemotherapy regimen.
What is the current status of trial NCT00290017?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 400 participants. The study started on 2006-02.
What interventions are being tested in trial NCT00290017?
The interventions under investigation include: pemetrexed (DRUG), talabostat (DRUG).
Who is sponsoring clinical trial NCT00290017?
This trial is sponsored by Point Therapeutics, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.